Transcript – Targeting Oncogenic Protein-Protein Interactions to Overcome Drug Resistance

In this project, we are focused on the development of inhibiters targeting oncogenic protein interactions, as we all know, the development of cancer drugs takes a long time and lots of money. However, even if a drug is developed, cancer cells often develop resistance to the drug. So, our goal in this project is to develop peptide inhibitor preventing oncogenic interaction between Kraki indescribable proteins. This interaction has been identified as a potential drug target to prevent cancer metastasis. Previously, we found in 1918 influenza virus hijacks human protein using a so-called Collingridge motive in this project to make the viral motive more drug like molecule recycling’s the linear peptide using a so-called Cyclopes approach.

However, cyclic peptide generated by this method is difficult to clarify for detailed characterization. So, we designed a modified Cyclopes, which allows us to purify cyclic peptide. Summarizing the result, we showed that our modified approach works for the invitro purification of cyclic peptide. We also found that the secularization changes the binding properties because of its confirmation is different from its linear counterpart, is a little bit disappointing that the affinity was not as high as we initially expected. However, this result also highlights the value of our modified Cyclopes approach because we can characterize the cyclic peptide for further optimization. Based on this, Finding Our Future study will focus on the optimization of the sequence and length of the cyclic peptide. Thank you.